Imaging the onset and progression of Alzheimer's disease: Implications for prevention trials

Journal of Alzheimer's Disease

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Liang, Yuying ^a   Ryan, Natalie S ^a   Schott, Jonathan M ^a   Fox, Nick C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; clinical trials; familial Alzheimer's disease; magnetic resonance imaging; presymptomatic

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DISEASE COURSE; FAMILIAL DISEASE; HUMAN; IN VIVO STUDY; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

EID: 84872512557     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-129010     Document Type: Review

References (75)

1. DeCarli C, Kaye JA, Horwitz B, Rapoport SI (1990) Critical analysis of the use of computer-Assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology 40, 872-883
2. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259
3. Hyman BT,Van HoesenGW, Damasio AR, Barnes CL (1984) Alzheimer's disease: Cell-Specific pathology isolates the hippocampal formation. Science 225, 1168-1170
4. Ball M, Fisman M, Hachinski V, Blume W, Fox A, Kral V (1985) A new definition of Alzheimer's disease: A hippocampal dementia. Lancet 1, 14-16
5. West M, Coleman P, Flood D, Troncoso J (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 2, 769-772
6. Seab JP, Jagust WJ,Wong STS, Roos MS, Reed BR, Budinger TF (1988) Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magnc Reson Med 8, 200-208
7. Kesslak JP, Nalcioglu O, Cotman CW (1991) Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 41, 51-54
8. Jack CR, Petersen RC, O'Brien PC, Tangalos EG (1992) MRbased hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 42, 183-188
9. Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F (1993) Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 50, 949-954
10. Leh'ericy S, Baulac M, Chiras J, Pi'erot L, Martin N, Pillon B, Deweer B, Dubois B, Marsault C (1994) Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. AJNR Am J Neuroradiol 15, 929-937
11. Laakso MP, Soininen H, Partanen K, Helkala EL, Hartikainen P, Vainio P, Hallikainen M, Hánninen T, Riekkinen PJ (1995) Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions. J Neural Transm Park Dis Dement Sect 9, 73-86
12. Brouwers N, Sleegers K, Van Broeckhoven C (2008) Molecular genetics of Alzheimer's disease: An update. Ann Med 40, 562-583
13. Bekris LM, Yu C-E, Bird T, Tsuang D (2010) Genetics of Alzheimer's disease. J Geriatr Psychiatry Neurol 23, 213-227
14. Rossor MN, Fox NC, Freeborough PA, Harvey RJ (1996) Clinical features of sporadic and familial Alzheimer's disease. Neurodegeneration 5, 393-397
15. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM (1996) Presymptomatic hippocampal atrophy in Alzheimer's disease A longitudinal MRI study. Brain 119 (Pt 6), 2001-2007
16. Fox NC, Warrington EK, Stevens JM, Rossor MN (1996) Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann N Y Acad Sci 777, 226-232
17. Freeborough PA, Woods RP, Fox N (1996) Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. J Comp Asst Tomogr 20, 1012-1022
18. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60, 989-994
19. Fox NC, Freeborough PA (1997) Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimer's disease. J Magn Reson Imaging 7, 1069-1075
20. Fox NC, Warrington EK, Rossor MN (1999) Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 353, 2125
21. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC (2005) Measuring atrophy in Alzheimer disease: A serial MRI study over 6 and 12 months. Neurology 65, 119-124
22. O'Brien JT, Paling S, Barber R (2001) Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 56, 1386-1388
23. Fox NC, Scahill RI,CrumWR,RossorMN(1999) Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52, 1687-1689
24. Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC (2008) Volumetric MRI and cognitive measures in Alzheimer disease: Comparison of markers of progression. J Neurol 255, 567-574
25. Schott JM, Crutch SJ, Frost C, Warrington EK, Rossor MN, Fox NC (2008) Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. Neuropsychologia 46, 1732-1737
26. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132 1355-1365
27. Fox NC, Cousens S, Scahill R, Harvey RJ, RossorMN(2000) Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57, 339-344
28. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo J-M (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562
29. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572
30. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M (2009) Long-Term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Curr Alzheimer Res 6, 144-151
31. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR (2008) Long-Term effects of A 42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223
32. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Weiner MW, Fox NC, Ourselin S (2010) Robust atrophy rate measurement in Alzheimer's disease using multi-Site serial MRI: Tissue-Specific intensity normalization and parameter selection. NeuroImage 50, 516-523
33. Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S (2010) Automated cross-Sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. NeuroImage 51, 1345-1359
34. Frost C, Kenward MG, Fox NC (2008) Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency? Stat Med 27, 3717-3731
35. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, Rossor MN, Fox NC (2006) Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. J Neurol 253, 1147-1153
36. Schott J, Fox N, Frost C, Chan D, Jenkin R, Rossor M (2003) Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 53, 181-188
37. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer's disease: A serial MRI study. Lancet Neurol 5, 828-834
38. Chan D, Janssen JJC, Whitwell JJL, Watt HCH, Jenkins R, Frost C, Rossor MN, Fox NC (2003) Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: Longitudinal MRI study. Lancet 362, 1121-1122
39. Freeborough PA, Fox NC (1998) Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. J Comp Asst Tomogr 22, 838-843
40. Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW (1999) In vivo evidence for post-Adolescent brain maturation in frontal and striatal regions. Nat Neurosci 2, 859-861
41. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN (2001) Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358, 201-205
42. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC (2002) Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A 99, 4703-4707
43. Kennedy AM, Rossor MN, Frackowiak RS (1995) Positron emission tomography in familial Alzheimer disease. Alz Dis Assoc Disord 9, 17-20
44. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42, 85-94
45. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S,Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97, 6037-6042
46. Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, Kaplan EF, D'Agostino RB (1995) The "preclinical phase" of probable Alzheimer's disease. A 13-Year prospective study of the Framingham cohort. Arch Neurol 52, 485-490
47. Fox NC,Warrington EK, Seiffer AL, Agnew SK, Rossor MN (1998) Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease A longitudinal prospective study. Brain 121(Pt 9), 1631-1639
48. Chen P, RatcliffG, Belle SH, Cauley Ja, DeKosky ST, Ganguli M (2001) Patterns of cognitive decline in presymptomatic Alzheimer disease:Aprospective community study. Arch Gen Psychiatry 58, 853-858
49. Morris JC, Price JL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-Stage Alzheimer's disease. J Mol Neurosci 17, 101-118
50. Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-Type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42, 1681-1688
51. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstro M, Savitcheva I, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstro B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55, 306-319
52. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased -Amyloid1-42 and increased tau levels in cerebrospinal tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 2094-2103
53. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis Ca, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452
54. Fagan AM, Roe CM, Xiong C, Mintun Ma, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-Amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349
55. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, Keefe GO, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283
56. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128
57. Sperling RA, Aisen PS, Beckett LA, Bennett Da, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
58. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: Diagnosis of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153
59. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P (2010) EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17, 1236-1248
60. National Institute for Health and Clinical Excellence (2011) Dementia: Supporting people with dementia and their carers in health and social care, http://www.nice.org.uk/CG42
61. Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, Shen Q, Raj A, Small B, BarkerW, Schofield E,Wu Y, Potter H (2008) Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 1986-1992
62. de Leon M, Golomb J, George A, Convit A, Tarshish C, McRae T, De Santi S, Smith G, Ferris S, Noz M (1993) The radiologic prediction of Alzheimer disease: The atrophic hippocampal formation. AJNRAmJ Neuroradiol 14, 897-906
63. Jack C, Peterson R, Yue CX, O'Brien P, Smith GE, Ivnik R, Boeve B,Waring S, Tanglaos E, Kokmen E (1999) Prediction ofADwith MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403
64. Korf ESC, Wahlund L-O, Visser PJ, Scheltens P (2004) Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63, 94-100
65. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR, Scheltens P (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64, 108-115
66. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746
67. Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, Leschziner G, Rossor AM, Stevens JM, Cipolotti L, Rossor MN (2001) Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol 49, 433-442
68. Bouwman FH, Schoonenboom SNM, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P (2007)CSFbiomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 28, 1070-1074
69. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R,Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 73, 754-760
70. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nature Rev Neurol 6, 67-77
71. Mangialasche F, Solomon A,Winblad B, Mecocci P, Kivipelto M(2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9, 702-716
72. Bateman RJ, Aisen PS, Strooper BD, Fox NC, Lemere CA, Ringman JM (2011) Autosomal-Dominant Alzheimer's disease: Areviewand proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 3, 1-13
73. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Archives Neurol 67, 949-956
74. Schott JM, Bartlett JW, Fox NC, Barnes J (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A-1-42. Ann Neurol 68, 825-834
75. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein M, a, Barkhof F, van der Flier WM, Scheltens P (2010) Wholebrain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging 31, 758-764